keyword
MENU ▼
Read by QxMD icon Read
search

Yttrium 90

keyword
https://www.readbyqxmd.com/read/27890462/radiation-pneumonitis-following-hepatic-yttrium-90-radioembolization
#1
Horacio Matías Castro, Esteban Javier Wainstein, Joaquin Maritano Furcada
No abstract text is available yet for this article.
November 24, 2016: Archivos de Bronconeumología
https://www.readbyqxmd.com/read/27884683/yttrium-90-radioembolization-with-resin-microspheres-without-routine-embolization-of-the-gastroduodenal-artery
#2
Thomas J Ward, John D Louie, Daniel Y Sze
PURPOSE: To evaluate safety of resin microsphere radioembolization (RE) without prophylactic embolization of the gastroduodenal artery (GDA). MATERIALS AND METHODS: Between July 2013 and April 2015, all patients undergoing RE with resin microspheres for liver-dominant metastatic disease were treated without routine embolization of the GDA. Selective embolization of distal hepaticoenteric vessels was performed if identified by digital subtraction angiography, cone-beam computed tomography, or technetium-99m macroaggregated albumin scintigraphy...
November 21, 2016: Journal of Vascular and Interventional Radiology: JVIR
https://www.readbyqxmd.com/read/27878478/liver-resection-after-selective-internal-radiation-therapy-with-yttrium-90-is-safe-and-feasible-a-bi-institutional-analysis
#3
G Paul Wright, J Wallis Marsh, Manish K Varma, Michael G Doherty, David L Bartlett, Mathew H Chung
BACKGROUND: Treatment with yttrium-90 (Y90) microspheres has emerged as a viable liver-directed therapy for patients with unresectable tumors and those outside transplantation criteria. A select number of patients demonstrate a favorable response and become candidates for surgical resection. METHODS: Patients who underwent selective internal radiation therapy (SIRT) with Y90 microspheres at two institutions were reviewed. Patients who underwent liver resection were included in the study...
November 22, 2016: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/27875761/prognostic-value-of-post-yttrium-90-radioembolization-therapy-18f-fluorodeoxyglucose-positron-emission-tomography-in-patients-with-liver-tumors
#4
Sebastian Obrzut, Kevin McCammack, Karam W Badran, Anthony Balistreri, Evan Ou, Brian J Nguyen, Carl K Hoh, Steven C Rose
OBJECTIVE: This study assessed the benefit of post-therapy (18)F-FDG PET/CT versus CT alone in identifying malignant liver tumor progression following radioembolization with Y-90 microspheres. METHODS: 24 patients with 44 liver tumors underwent CT imaging pre-radioembolization and PET/CT post-radioembolization. Predictive value of Response Evaluation Criteria in Solid Tumors (RECIST 1.1), The World Health Organization (WHO), mRECIST and European Association for the Study of the Liver (EASL) with PET/CT versus CT alone was assessed...
November 16, 2016: Clinical Imaging
https://www.readbyqxmd.com/read/27870679/new-developments-in-interventional-oncology-liver-metastases-from-colorectal-cancer
#5
Joseph R Kallini, Ahmed Gabr, Nadine Abouchaleh, Rehan Ali, Ahsun Riaz, Robert J Lewandowski, Riad Salem
Colorectal cancer is the third leading cause of cancer death in the United States. Although hepatic excision is the first-line treatment for colorectal liver metastasis (CRLM), few patients are candidates. Locoregional therapy (LRT) encompasses minimally invasive techniques practiced by interventional radiology. These include ablative treatments (radiofrequency ablation, microwave ablation, and cryosurgical ablation) and transcatheter intra-arterial therapy (hepatic arterial infusion chemotherapy, transarterial "bland" embolization, transarterial chemoembolization, and radioembolization with yttrium 90)...
November 2016: Cancer Journal
https://www.readbyqxmd.com/read/27826686/resin-based-yttrium-90-microspheres-for-unresectable-and-failed-first-line-chemotherapy-intrahepatic-cholangiocarcinoma-preliminary-results
#6
Zhongzhi Jia, Ricardo Paz-Fumagalli, Gregory Frey, David M Sella, J Mark McKinney, Weiping Wang
PURPOSE: To evaluate the value of resin-based yttrium-90 ((90)Y) radioembolization for unresectable and failed first-line chemotherapy (cisplatin plus gemcitabine) intrahepatic cholangiocarcinoma (ICC). METHODS: From February 2006 to September 2015, a retrospective study was conducted of all patients who underwent resin-based (90)Y therapy for unresectable and failed first-line chemotherapy ICC. Tumor response was assessed using modified RECIST criteria; side effects were assessed using Common Terminology Criteria for Adverse Events version 4...
November 8, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27821083/single-administration-of-selective-internal-radiation-therapy-versus-continuous-treatment-with-sorafenib-in-locally-advanced-hepatocellular-carcinoma-sirvenib-study-protocol-for-a-phase-iii-randomized-controlled-trial
#7
Mihir Gandhi, Su Pin Choo, Choon Hua Thng, Say Beng Tan, Albert Su Chong Low, Peng Chung Cheow, Anthony Soon Whatt Goh, Kiang Hiong Tay, Richard Hoau Gong Lo, Brian Kim Poh Goh, Jen San Wong, David Chee Eng Ng, Khee Chee Soo, Wei Ming Liew, Pierce K H Chow
BACKGROUND: Approximately 20 % of hepatocellular carcinoma (HCC) patients diagnosed in the early stages may benefit from potentially curative ablative therapies such as surgical resection, transplantation or radiofrequency ablation. For patients not eligible for such options, prognosis is poor. Sorafenib and Selective Internal Radiation Therapy (SIRT) are clinically proven treatment options in patients with unresectable HCC, and this study aims to assess overall survival following either SIRT or Sorafenib therapy for locally advanced HCC patients...
November 7, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27810122/carbon-footprint-assessment-of-recycling-technologies-for-rare-earth-elements-a-case-study-of-recycling-yttrium-and-europium-from-phosphor
#8
Allen H Hu, Chien-Hung Kuo, Lance H Huang, Chao-Chin Su
Rare earth elements are key raw materials in high-technology industries. Mining activities and manufacturing processes of such industries have caused considerable environmental impacts, such as soil erosion, vegetation destruction, and various forms of pollution. Sustaining the long-term supply of rare earth elements is difficult because of the global shortage of rare earth resources. The diminishing supply of rare earth elements has attracted considerable concern because many industrialized countries regarded such elements as important strategic resources for economic growth...
October 31, 2016: Waste Management
https://www.readbyqxmd.com/read/27806615/a-volume-equivalent-spherical-necrosis-tumor-normal-liver-model-for-estimating-absorbed-dose-in-yttrium-90-microsphere-therapy
#9
Chin-Hui Wu, Yi-Jen Liao, Tzung-Yi Lin, Yu-Cheng Chen, Shung-Shung Sun, Yen-Wan Hsueh Liu, Shih-Ming Hsu
PURPOSE: Primary hepatocellular carcinoma and metastatic liver tumors are highly malignant tumors in Asia. The incidence of fatal liver cancer is also increasing in the United States. The aim of this study was to establish a spherical tumor model and determine its accuracy in predicting the absorbed dose in yttrium-90 (Y-90) microsphere therapy for liver cancer. METHODS: Liver morphology can be approximated by a spherical model comprising three concentric regions representing necrotic, tumor, and normal liver tissues...
November 2016: Medical Physics
https://www.readbyqxmd.com/read/27803608/combined-sorafenib-and-yttrium-90-radioembolization-for-the-treatment-of-advanced-hepatocellular-carcinoma
#10
A Salman, E Simoneau, M Hassanain, P Chaudhury, L M Boucher, D Valenti, T Cabrera, C Nudo, P Metrakos
BACKGROUND AND AIMS: In this pilot study, we assessed the safety and tolerability of combining sorafenib with (90)Y radioembolization for the treatment of unresectable hepatocellular carcinoma (hcc). METHODS: The study, conducted prospectively during 2009-2012, included eligible patients with unresectable hcc and a life expectancy of at least 12 weeks. Each patient received sorafenib (400 mg twice daily) for 6-8 weeks before (90)Y treatment. Safety and tolerability were assessed...
October 2016: Current Oncology
https://www.readbyqxmd.com/read/27789090/a-hydrometallurgical-process-for-the-recovery-of-terbium-from-fluorescent-lamps-experimental-design-optimization-of-acid-leaching-process-and-process-analysis
#11
Valentina Innocenzi, Nicolò Maria Ippolito, Ida De Michelis, Franco Medici, Francesco Vegliò
Terbium and rare earths recovery from fluorescent powders of exhausted lamps by acid leaching with hydrochloric acid was the objective of this study. In order to investigate the factors affecting leaching a series of experiments was performed in according to a full factorial plan with four variables and two levels (4(2)). The factors studied were temperature, concentration of acid, pulp density and leaching time. Experimental conditions of terbium dissolution were optimized by statistical analysis. The results showed that temperature and pulp density were significant with a positive and negative effect, respectively...
October 24, 2016: Journal of Environmental Management
https://www.readbyqxmd.com/read/27782730/comparison-of-quantitative-y-90-spect-and-non-time-of-flight-pet-imaging-in-post-therapy-radioembolization-of-liver-cancer
#12
Jianting Yue, Thibault Mauxion, Diane K Reyes, Martin A Lodge, Robert F Hobbs, Xing Rong, Yinfeng Dong, Joseph M Herman, Richard L Wahl, Jean-François H Geschwind, Eric C Frey
PURPOSE: Radioembolization with yttrium-90 microspheres may be optimized with patient-specific pretherapy treatment planning. Dose verification and validation of treatment planning methods require quantitative imaging of the post-therapy distribution of yttrium-90 (Y-90). Methods for quantitative imaging of Y-90 using both bremsstrahlung SPECT and PET have previously been described. The purpose of this study was to compare the two modalities quantitatively in humans. METHODS: Calibration correction factors for both quantitative Y-90 bremsstrahlung SPECT and a non-time-of-flight PET system without compensation for prompt coincidences were developed by imaging three phantoms...
October 2016: Medical Physics
https://www.readbyqxmd.com/read/27771496/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-as-part-of-reduced-intensity-conditioning-with-melphalan-fludarabine-%C3%A2-thiotepa-for-allogeneic-transplantation-in-relapsed-or-refractory-aggressive-b-cell-lymphoma-a-geltamo-trial
#13
Monica Cabrero, Alejandro Martin, Javier Briones, Jorge Gayoso, Isidro Jarque, Javier López, Carlos Grande, Inmaculada Heras, Reyes Arranz, Teresa Bernal, Estefania Perez-Lopez, Oriana López-Godino, Eulogio Conde, Dolores Caballero
We designed a phase II clinical trial including Y-90 ibritumomab-tiuxetan as part of a reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (AlloSCT) in high-risk non-Hodgkin lymphoma (Clinical Trials Identifier: NCT00644371). Eligible patients had high-risk relapsed/refractory aggressive lymphoma. The conditioning regimen consisted of rituximab 250 mg (days -21 and -14), Y-90 ibritumomab IV (.4 m Ci/kg, day -14), fludarabine 30 mg/m(2) i.v. (days -3 and -2) plus melphalan 70 mg/m(2) i...
October 19, 2016: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27748320/a-systematic-review-on-the-safety-and-effectiveness-of-yttrium-90-radioembolization-for-hepatocellular-carcinoma-with-portal-vein-tumor-thrombosis
#14
Zhongzhi Jia, Guomin Jiang, Feng Tian, Chunfu Zhu, Xihu Qin
BACKGROUND/AIM: Over the past two decades, several advances have been made in the management of patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Yttrium-90 ( 90 Y) radioembolization has recently been made a treatment option for patients with HCC and PVTT. However, there is still a need to systematicly evaluate the outcomes of 90 Y radioembolization for HCC and PVTT. We aimed to assess the safety and effectiveness of 90 Y radioembolization for HCC and PVTT...
September 2016: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/27748281/preliminary-evaluation-of-indigenous-90-y-labelled-microspheres-for-therapy-of-hepatocellular-carcinoma
#15
Suresh Subramanian, Usha Pandey, Pradip Chaudhari, Monica Tyagi, Sanjay Gupta, Geetanjali Singh, Ashutosh Dash, Grace Samuel, Meera Venkatesh
BACKGROUND & OBJECTIVES: Yttrium-90 ( 90 Y)-based radioembolization has been employed to treat hepatocellular carcinoma (HCC) as commercial radioactive glass and polymeric resin microspheres. However, in India and other Asian countries, these preparations must be imported and are expensive, validating the need for development of indigenous alternatives. This work was aimed to develop an economically and logistically favourable indigenous alternative to imported radioembolizing agents for HCC therapy...
May 2016: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/27743088/histological-comparison-of-kidney-tissue-following-radioembolization-with-yttrium-90-resin-microspheres-and-embolization-with-bland-microspheres
#16
Suresh de Silva, Simon Mackie, Peter Aslan, David Cade, Warick Delprado
BACKGROUND: Intra-arterial brachytherapy with yttrium-90 ((90)Y) resin microspheres (radioembolization) is a procedure to selectively deliver high-dose radiation to tumors. The purpose of this research was to compare the radioembolic effect of (90)Y-radioembolization versus the embolic effect of bland microspheres in the porcine kidney model. METHODS: In each of six pigs, ~25-33 % of the kidney volume was embolized with (90)Y resin microspheres and an equivalent number of bland microspheres in the contralateral kidney...
December 2016: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/27730823/update-on-novel-trends-in-pet-ct-technology-and-its-clinical-applications
#17
Stephan Walrand, Michel Hesse, François Jamar
After a brief history of the major evolutions of PET since its introduction in 1972, this paper reviews the recent improvements and novel trends in PET with a special focus on time of flight that is currently the major research topic. Novel emerging acquisition modalities, such as dual tracer acquisition, inline hadron therapy dose imaging and yttrium-90 imaging are reviewed.
October 12, 2016: British Journal of Radiology
https://www.readbyqxmd.com/read/27720205/a-novel-conformal-superficial-high-dose-rate-brachytherapy-device-for-the-treatment-of-nonmelanoma-skin-cancer-and-keloids
#18
Clara Ferreira, Daniel Johnson, Karl Rasmussen, Clinton Leinweber, Salahuddin Ahmad, Jae Won Jung
PURPOSE: To develop a novel conformal superficial brachytherapy (CSBT) device as a treatment option for the patient-specific radiation therapy of conditions including superficial lesions, postsurgical positive margins, Dupuytren's contractures, keloid scars, and complex anatomic sites (eyelids, nose, ears, etc.). METHODS AND MATERIALS: A preliminary CSBT device prototype was designed, built, and tested using readily available radioactive seeds. Iodine-125 ((125)I) seeds were independently guided to the treatment surface to conform to the target...
October 3, 2016: Brachytherapy
https://www.readbyqxmd.com/read/27689207/multimodal-therapy-including-yttrium-90-radioembolization-as-a-bridging-therapy-to-liver-transplantation-for-a-huge-and-locally-advanced-intrahepatic-cholangiocarcinoma
#19
Michel Rayar, Giovanni Battista Levi Sandri, Pauline Houssel-Debry, Christophe Camus, Laurent Sulpice, Karim Boudjema
Treatment of intrahepatic cholangiocarcinoma remains a major challenge. For an unresectable lesion without extrahepatic spread, liver transplantation could be a potential solution but it is still associated with poor oncologic results owing to the absence of effective neoadjuvant treatment. We report the case of a young man with locally advanced intrahepatic cholangiocarcinoma presenting with multiple intrahepatic metastases and vascular structure involvement. The lesion was significantly downstaged by a multimodal therapy including intra-arterial Yttrium-90 radioembolization, systemic chemotherapy and external radiotherapy, allowing liver transplantation...
September 2016: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/27688476/optimization-of-image-reconstruction-for-yttrium-90-sirt-on-a-lyso-pet-ct-system-using-a-bayesian-penalized-likelihood-reconstruction-algorithm
#20
Lisa M Rowley, Kevin M Bradley, Philip Boardman, Aida Hallam, Daniel R McGowan
: Imaging on a gamma camera with Yttrium-90 ((90)Y) following selective internal radiotherapy (SIRT) may allow for verification of treatment delivery but suffers relatively poor spatial resolution and imprecise dosimetry calculation. (90)Y Positron Emission Tomography (PET) / Computed Tomography (CT) imaging is possible on 3D, time-of-flight machines however images are usually poor due to low count statistics and noise. A new PET reconstruction software using a Bayesian penalized likelihood (BPL) reconstruction algorithm (termed Q...
September 29, 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
keyword
keyword
8545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"